The Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the future.
BACKGROUND: Risk sharing schemes represent an innovative and important approach to the problems of rationing and achieving cost-effectiveness in high cost or controversial health interventions. This study aimed to assess the feasibility of risk sharing schemes, looking at long term clinical outcomes...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2009
|
| _version_ | 1797079218368020480 |
|---|---|
| author | Pickin, M Cooper, C Chater, T O'Hagan, A Abrams, K Cooper, N Boggild, M Palace, J Ebers, G Chilcott, J Tappenden, P Nicholl, J |
| author_facet | Pickin, M Cooper, C Chater, T O'Hagan, A Abrams, K Cooper, N Boggild, M Palace, J Ebers, G Chilcott, J Tappenden, P Nicholl, J |
| author_sort | Pickin, M |
| collection | OXFORD |
| description | BACKGROUND: Risk sharing schemes represent an innovative and important approach to the problems of rationing and achieving cost-effectiveness in high cost or controversial health interventions. This study aimed to assess the feasibility of risk sharing schemes, looking at long term clinical outcomes, to determine the price at which high cost treatments would be acceptable to the NHS. METHODS: This case study of the first NHS risk sharing scheme, a long term prospective cohort study of beta interferon and glatiramer acetate in multiple sclerosis (MS) patients in 71 specialist MS centres in UK NHS hospitals, recruited adults with relapsing forms of MS, meeting Association of British Neurologists (ABN) criteria for disease modifying therapy. Outcome measures were: success of recruitment and follow up over the first three years, analysis of baseline and initial follow up data and the prospect of estimating the long term cost-effectiveness of these treatments. RESULTS: Centres consented 5560 patients. Of the 4240 patients who had been in the study for a least one year, annual review data were available for 3730 (88.0%). Of the patients who had been in the study for at least two years and three years, subsequent annual review data were available for 2055 (78.5%) and 265 (71.8%) patients respectively. Baseline characteristics and a small but statistically significant progression of disease were similar to those reported in previous pivotal studies. CONCLUSION: Successful recruitment, follow up and early data analysis suggest that risk sharing schemes should be able to deliver their objectives. However, important issues of analysis, and political and commercial conflicts of interest still need to be addressed. |
| first_indexed | 2024-03-07T00:42:38Z |
| format | Journal article |
| id | oxford-uuid:8396d2a2-65ae-4982-8b5a-dd9b68bdc887 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:42:38Z |
| publishDate | 2009 |
| record_format | dspace |
| spelling | oxford-uuid:8396d2a2-65ae-4982-8b5a-dd9b68bdc8872022-03-26T21:45:07ZThe Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the future.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:8396d2a2-65ae-4982-8b5a-dd9b68bdc887EnglishSymplectic Elements at Oxford2009Pickin, MCooper, CChater, TO'Hagan, AAbrams, KCooper, NBoggild, MPalace, JEbers, GChilcott, JTappenden, PNicholl, JBACKGROUND: Risk sharing schemes represent an innovative and important approach to the problems of rationing and achieving cost-effectiveness in high cost or controversial health interventions. This study aimed to assess the feasibility of risk sharing schemes, looking at long term clinical outcomes, to determine the price at which high cost treatments would be acceptable to the NHS. METHODS: This case study of the first NHS risk sharing scheme, a long term prospective cohort study of beta interferon and glatiramer acetate in multiple sclerosis (MS) patients in 71 specialist MS centres in UK NHS hospitals, recruited adults with relapsing forms of MS, meeting Association of British Neurologists (ABN) criteria for disease modifying therapy. Outcome measures were: success of recruitment and follow up over the first three years, analysis of baseline and initial follow up data and the prospect of estimating the long term cost-effectiveness of these treatments. RESULTS: Centres consented 5560 patients. Of the 4240 patients who had been in the study for a least one year, annual review data were available for 3730 (88.0%). Of the patients who had been in the study for at least two years and three years, subsequent annual review data were available for 2055 (78.5%) and 265 (71.8%) patients respectively. Baseline characteristics and a small but statistically significant progression of disease were similar to those reported in previous pivotal studies. CONCLUSION: Successful recruitment, follow up and early data analysis suggest that risk sharing schemes should be able to deliver their objectives. However, important issues of analysis, and political and commercial conflicts of interest still need to be addressed. |
| spellingShingle | Pickin, M Cooper, C Chater, T O'Hagan, A Abrams, K Cooper, N Boggild, M Palace, J Ebers, G Chilcott, J Tappenden, P Nicholl, J The Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the future. |
| title | The Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the future. |
| title_full | The Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the future. |
| title_fullStr | The Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the future. |
| title_full_unstemmed | The Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the future. |
| title_short | The Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the future. |
| title_sort | multiple sclerosis risk sharing scheme monitoring study early results and lessons for the future |
| work_keys_str_mv | AT pickinm themultiplesclerosisrisksharingschememonitoringstudyearlyresultsandlessonsforthefuture AT cooperc themultiplesclerosisrisksharingschememonitoringstudyearlyresultsandlessonsforthefuture AT chatert themultiplesclerosisrisksharingschememonitoringstudyearlyresultsandlessonsforthefuture AT ohagana themultiplesclerosisrisksharingschememonitoringstudyearlyresultsandlessonsforthefuture AT abramsk themultiplesclerosisrisksharingschememonitoringstudyearlyresultsandlessonsforthefuture AT coopern themultiplesclerosisrisksharingschememonitoringstudyearlyresultsandlessonsforthefuture AT boggildm themultiplesclerosisrisksharingschememonitoringstudyearlyresultsandlessonsforthefuture AT palacej themultiplesclerosisrisksharingschememonitoringstudyearlyresultsandlessonsforthefuture AT ebersg themultiplesclerosisrisksharingschememonitoringstudyearlyresultsandlessonsforthefuture AT chilcottj themultiplesclerosisrisksharingschememonitoringstudyearlyresultsandlessonsforthefuture AT tappendenp themultiplesclerosisrisksharingschememonitoringstudyearlyresultsandlessonsforthefuture AT nichollj themultiplesclerosisrisksharingschememonitoringstudyearlyresultsandlessonsforthefuture AT pickinm multiplesclerosisrisksharingschememonitoringstudyearlyresultsandlessonsforthefuture AT cooperc multiplesclerosisrisksharingschememonitoringstudyearlyresultsandlessonsforthefuture AT chatert multiplesclerosisrisksharingschememonitoringstudyearlyresultsandlessonsforthefuture AT ohagana multiplesclerosisrisksharingschememonitoringstudyearlyresultsandlessonsforthefuture AT abramsk multiplesclerosisrisksharingschememonitoringstudyearlyresultsandlessonsforthefuture AT coopern multiplesclerosisrisksharingschememonitoringstudyearlyresultsandlessonsforthefuture AT boggildm multiplesclerosisrisksharingschememonitoringstudyearlyresultsandlessonsforthefuture AT palacej multiplesclerosisrisksharingschememonitoringstudyearlyresultsandlessonsforthefuture AT ebersg multiplesclerosisrisksharingschememonitoringstudyearlyresultsandlessonsforthefuture AT chilcottj multiplesclerosisrisksharingschememonitoringstudyearlyresultsandlessonsforthefuture AT tappendenp multiplesclerosisrisksharingschememonitoringstudyearlyresultsandlessonsforthefuture AT nichollj multiplesclerosisrisksharingschememonitoringstudyearlyresultsandlessonsforthefuture |